Century Therapeutics (NASDAQ:IPSC – Get Rating) had its price target decreased by Bank of America from $23.00 to $20.00 in a report released on Friday, The Fly reports. Bank of America‘s price target indicates a potential upside of 418.13% from the company’s previous close.
Several other research analysts also recently commented on the stock. Chardan Capital began coverage on shares of Century Therapeutics in a research note on Tuesday, December 27th. They issued a “buy” rating and a $19.00 target price on the stock. HC Wainwright decreased their target price on shares of Century Therapeutics from $19.00 to $17.00 and set a “buy” rating on the stock in a research note on Friday. Piper Sandler decreased their target price on shares of Century Therapeutics from $24.00 to $14.00 and set an “overweight” rating on the stock in a research note on Friday, January 6th. EF Hutton Acquisition Co. I reaffirmed a “buy” rating and issued a $16.00 target price on shares of Century Therapeutics in a research note on Thursday. Finally, SVB Leerink decreased their target price on shares of Century Therapeutics from $20.00 to $14.00 and set an “outperform” rating on the stock in a research note on Friday, January 6th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $19.00.
Century Therapeutics Stock Down 3.0 %
Shares of NASDAQ IPSC opened at $3.86 on Friday. The company has a quick ratio of 13.44, a current ratio of 13.44 and a debt-to-equity ratio of 0.02. Century Therapeutics has a 52 week low of $3.54 and a 52 week high of $14.02. The firm’s fifty day moving average is $4.53 and its 200 day moving average is $7.68. The company has a market cap of $227.62 million, a price-to-earnings ratio of -1.96 and a beta of 0.69.
Institutional Trading of Century Therapeutics
About Century Therapeutics
Century Therapeutics, Inc, a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma.
- Get a free copy of the StockNews.com research report on Century Therapeutics (IPSC)
- MarketBeat Week in Review – 3/13 – 3/17
- This Small Tech With Big Growth Prospects Is Nearing A Buy Point
- Don’t Chase FedEx Higher, Wait For The Pullback
- 3 Stocks For A Defensive Tech Portfolio
- Milk the Dividends on These 3 Cash Cows
Receive News & Ratings for Century Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Century Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.